# FRED HUTCHINSON CANCER CENTER: Optimizing the Efficacy and Safety of CD33-Targeted Immunotherapy for Acute Myeloid Leukemia and Other CD33+ Disorders

**Lab Budget Score:** 40/100

| Field | Value |
|---|---|
| Organization | FRED HUTCHINSON CANCER CENTER |
| Location | SEATTLE, WA |
| Project | Optimizing the Efficacy and Safety of CD33-Targeted Immunotherapy for Acute Myeloid Leukemia and Other CD33+ Disorders |
| Project number | 5R50CA274319-04 |
| Mechanism | R50 |
| Institute | National Cancer Institute |
| Award | $161,878 |
| Awarded | 2026-09-02 |
| Project period | 2023-08-15 to 2028-07-31 |
| UEI | TJFZLPP6NYL6 |

## Why this score
- Award of $161,878.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11399862). Last refreshed: 2026-11-04T21:37:56.465Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.